Vericel Corporation $VCEL Stake Raised by Geneva Capital Management LLC

Key Points

• Geneva Capital Management raised its stake in Vericel by 9% to 1,946,305 shares — about 3.85% ownership valued at roughly $61.25 million.
• Multiple other institutions also increased positions (notably BNP Paribas +86.9%, WINTON +104.1%, Rhenman +101.7%, Russell +48.2%), indicating broad institutional buying interest.
• Vericel reported quarterly EPS $0.45 (in line with estimates) and revenue of $92.92M, up 23.3% YoY; the stock trades at a ~$1.7B market cap with a consensus rating of "Moderate Buy" and a consensus price target of $56.

Geneva Capital Management LLC raised its holdings in Vericel Corporation (NASDAQ:VCEL - Free Report) by 9.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,946,305 shares of the biotechnology company's stock after acquiring an additional 161,378 shares during the quarter. Geneva Capital Management LLC owned 3.85% of Vericel worth $61,250,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. BNP Paribas Financial Markets raised its holdings in shares of Vericel by 86.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,091 shares of the biotechnology company's stock worth $1,828,000 after purchasing an additional 27,009 shares in the last quarter. Swiss National Bank grew its position in Vericel by 2.0% in the third quarter. Swiss National Bank now owns 97,600 shares of the biotechnology company's stock worth $3,071,000 after buying an additional 1,900 shares during the last quarter. WINTON GROUP Ltd grew its position in Vericel by 104.1% in the third quarter. WINTON GROUP Ltd now owns 34,766 shares of the biotechnology company's stock worth $1,094,000 after buying an additional 17,730 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Vericel by 48.2% in the third quarter. Russell Investments Group Ltd. now owns 176,105 shares of the biotechnology company's stock valued at $5,542,000 after buying an additional 57,249 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its position in shares of Vericel by 101.7% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 117,000 shares of the biotechnology company's stock valued at $3,682,000 after acquiring an additional 59,000 shares during the last quarter.

Vericel Price Performance

NASDAQ:VCEL opened at $33.40 on Wednesday. The stock has a market cap of $1.70 billion, a PE ratio of 107.74 and a beta of 1.22. Vericel Corporation has a fifty-two week low of $29.24 and a fifty-two week high of $49.10. The stock's 50-day moving average is $36.67 and its two-hundred day moving average is $36.03.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, hitting the consensus estimate of $0.45. Vericel had a net margin of 5.98% and a return on equity of 5.17%. The business had revenue of $92.92 million during the quarter, compared to analysts' expectations of $92.66 million. During the same period last year, the company posted $0.38 earnings per share. The firm's quarterly revenue was up 23.3% compared to the same quarter last year. On average, equities research analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on VCEL. Zacks Research lowered Vericel from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, November 12th. Leerink Partners reaffirmed an "outperform" rating and set a $46.00 target price on shares of Vericel in a report on Tuesday. Wall Street Zen lowered Vericel from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings restated a "hold (c-)" rating on shares of Vericel in a report on Monday, December 29th. Finally, Truist Financial reduced their price objective on shares of Vericel from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Thursday, December 18th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.